title: [Two patients with liver metastasis from gastric cancer who responded remarkably to combined therapy of 5'-DFUR and PSK].
abstract: Two patients with liver metastasis from gastric cancer who responded remarkably to a combined therapy of 5'-DFUR and PSK are reported. The first patient had liver metastases 8 months postoperatively. Her AFP level was 513 ng/ml and CEA was 30 ng/ml. After the combined therapy, all liver metastases showed a calcified change. Tumor markers of AFP and CEA decreased remarkably to the normal level within 3 weeks after the therapy. The patient had no relapse as of December 1999. The second patient with liver metastases was treated using the same combined therapy for 14 days preoperatively. The size of liver metastases had decreased remarkably by the time of the operation. A small metastasis of S8 (0.5 x 0.5 cm) was resected. No other liver metastasis was detected by intraoperative ultrasonography. The patient had no relapse as of February 2000. It is reported that PSK produces several cytokines which induce thymidine phosphorylase expression. The present report suggests that the upregulation of PyNPase might enhance the antitumor effect of 5'-DFUR.
authors.affiliation: Dept. of Surgery, Tokyo Metropolitan Bokutoh Hospital.
authors.forename: M
authors.initials: M
authors.lastname: Kitamura
authors.forename: N
authors.initials: N
authors.lastname: Umekita
authors.forename: S
authors.initials: S
authors.lastname: Inoue
authors.forename: Y
authors.initials: Y
authors.lastname: Miyamoto
authors.forename: T
authors.initials: T
authors.lastname: Maeshiro
authors.forename: A
authors.initials: A
authors.lastname: Saiura
authors.forename: S
authors.initials: S
authors.lastname: Tanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Kawahara
authors.forename: K
authors.initials: K
authors.lastname: Arai
authors.forename: Y
authors.initials: Y
authors.lastname: Iwasaki
authors.forename: M
authors.initials: M
authors.lastname: Ohashi
authors.forename: T
authors.initials: T
authors.lastname: Takahashi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D005743:Gastrectomy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000556:secondary*; D008875:Middle Aged; D010430:Pentosyltransferases / Q000378:metabolism; D011509:Proteoglycans / Q000008:administration & dosage; D057845:Pyrimidine Phosphorylases; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000473:pathology* / Q000601:surgery
chemical_list: D011509:Proteoglycans; D005467:Floxuridine; C010770:polysaccharide-K; D010430:Pentosyltransferases; D057845:Pyrimidine Phosphorylases; C025034:doxifluridine